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Background: An increasing prevalence of candidemia has been reported in Internal Medicine wards (IMWs). The
aim of our study was to identify risk factors for candidemia among non-neutropenic patients hospitalized in
IMWs.
Methods: A multicenter case–control study was performed in three hospitals in Italy. Patients developing
candidemia (cases) were compared to patients without candidemia (controls) matched by age, time of admis-
sion and duration of hospitalization. A logistic regression analysis identiﬁed risk factors for candidemia, and a
new risk score was developed. Validation was performed on an external cohort of patients.
Results:Overall, 951 patients (317 cases of candidemia and 634 controls) were included in the derivation cohort,
while 270 patients (90 patients with candidemia and 180 controls) constituted the validation cohort. Severe sep-
sis or septic shock, recent Clostridium difﬁcile infection, diabetes mellitus, total parenteral nutrition, chronic ob-
structive pulmonary disease, concomitant intravenous glycopeptide therapy, presence of peripherally inserted
central catheter, previous antibiotic therapy and immunosuppressive therapy were factors independently asso-
ciated with candidemia. The new risk score showed good area under the curve (AUC) values in both derivation
(AUC 0.973 95% CI 0.809–0.997, p b 0.001) and validation cohort (0.867 95% CI 0.710–0.931, p b 0.001). A thresh-
old of 3 leads to a sensitivity of 87% and a speciﬁcity of 83%.
Conclusion: Non-neutropenic patients admitted in IMWs have peculiar risk factors for candidemia. A new risk
score with a good performance could facilitate the identiﬁcation of candidates to early antifungal therapy.
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Hospital-acquired Candida bloodstream infections (BSI) represent
around the 9% of all nosocomial BSI [1]. Spanish data report an annual
incidence of 8.1 cases/100,000 inhabitants, 0.89/1000 admissions and
1.36/10,000 patient-days [2]. Candidemia has been extensively studied
in neutropenic patientswithhematologicalmalignancies or in non-neu-
tropenic ones admitted to intensive care units (ICUs) [3,4,5]. Moreover,
candidemia has been frequently reported in patients undergoing ab-
dominal surgery with anastomotic leakage or repeated laparotomies,
and Candida spp. account for approximately 3% of all surgical-related
peritoneal infections [4].
In recent years, a shift in candidemia hospital epidemiology has been
observed, with an increasing number of episodes (up to 59% of
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2nosocomial episodes) reported in patients cared for in Internal Medi-
cine wards (IMWs) [6–12]. Patients residing in IMWs are usually old,
with multiple comorbidities, and may present multiple risk factors for
candidemia.
An early identiﬁcation of patients presenting with risk factors for
candidemia is crucial becausemay help to generate a timely and appro-
priate diagnostic and therapeutic approach. The aim of our study is to
assess the role of speciﬁc risk factors for nosocomial candidemia in
non-neutropenic patients residing in IMWs.
2. Methods
2.1. Study population and study design
This retrospective multicenter case-control study was performed in
three tertiary-care hospitals, located in the Central Italy: Policlinico Um-
berto I, “Sapienza” University, Rome (1100 beds), San Giovanni-
Addolorata Hospital, Rome (700 beds), Azienda Ospedaliera
Universitaria Pisana, Pisa (800 beds). The study included cases observed
from December 2012 to December 2014. The local ethics committee
(“Ethics Committee Sapienza”) approved the study. According to local
and national policies, we attempted to obtain an informed consent
from survived patients that we were able to contact by phone or ambu-
latory visit; among remaining patients it was waived.
Patients aged ≥18 years cared for in IMWs with a deﬁnite diagnosis
of candidemia were included in the study and represented the case
group. IMWs included all medical wards other than surgical or intensive
care wards (general medicine, cardiology, pulmonology, nephrology,
rheumatology). Patients hospitalized in hematology and/or oncology
wards were excluded. Candidemia was deﬁned by at least one positive
blood culture yielding Candida spp. in a patient with fever and/or
other clinical signs of infection [13]. For patients with 2 or more epi-
sodes of candidemia, the subsequent episode was considered as a new
(incident) episode if it occurred after at least 30 days from the previous
one; in this case, we re-evaluated risk factors for each candidemia epi-
sode [14].
For each case, two controls matched for age (±2 years), date of hos-
pital admission and duration of hospitalization were selected
(cases:controls ratio 1:2). Matching for duration of hospitalization was
performed calculating the time between the day of admission and
candidemia occurrence (ﬁrst positive blood culture) of the index case
(duration categories: ≤7, 8–14, 15–21, 22–30, N30 days) and choosing
two controls with the same time of hospital stay. To ensure comparable
periods of risk exposure in both groups, each control had a length of
hospitalization similar to the time at risk of cases (deﬁned as the num-
ber of days from hospital admission to candidemia occurrence). Exclu-
sion criteria were candidemia documented outside IMWs,
age b 18 years and presence of neutropenia [deﬁned as absolute neutro-
phil count (ANC) of b500 cells/mm3 or an ANC that is expected to de-
crease to b500 cells/mm3 during the next 48 h] [14]. Moreover, we
excluded patients with diagnosis of any hematological malignancy.
Age b 18 years, presence of neutropenia and hematological malignancy
were exclusion criteria also for control patients. In this cohort of pa-
tients, risk factors independently associated with candidemia were
identiﬁed and were used to develop a new clinical risk score. The
score was further validated on an external cohort of patients hospital-
ized in IMWs in the tertiary-care University Hospital of Trieste (840
beds), sited in the Northern Italy. All cases were collected in the same
period in the derivation and validation cohort. In both populations,
the same abovementioned inclusion, exclusion and matching criteria
were applied.
2.2. Data collection and study deﬁnitions
Demographic data, underlying diseases, reason for hospital admis-
sion and severity of illness of patients with deﬁnite diagnosis of
candidemia were retrospectively reviewed by each investigator of the
four study centers on a standardized report form. The variables consid-
eredwere: age, sex, time at risk (deﬁned as the number of hospital days
from the admission in IMWs to the date of the ﬁrst positive blood cul-
ture for Candida spp.), comorbidities assessed by the Charlson comor-
bidity index. Information about diabetes mellitus, chronic liver
disease, malignancies, chronic obstructive pulmonary disease (COPD),
chronic renal failure, inﬂammatory bowel disease (IBD), acute pancrea-
titis, total parenteral nutrition (TPN) [15], central venous catheter (CVC)
or peripherally inserted central catheter (PICC), surgery in the previous
30 days, Clostridium difﬁcile infection (CDI), and concomitant antibiotic
therapy (deﬁned as exposure to antibiotics from at least 48 h before di-
agnosis of candidemia)were also collected. CDIwas deﬁned as the pres-
ence of diarrhea, deﬁned as passage of 3 or more unformed stools in 24
or fewer consecutive hours and a stool test result positive for the pres-
ence of toxigenic C. difﬁcile or its toxins. In the candidemia group, all
risk factors were assessed at the onset of candidemia (date of positivity
of blood cultures). On the same hand, in the control group risk factors
were collected after a period of hospitalization as long as the time at
risk of cases; this period could be named “pseudo-date of diagnosis”. Ac-
cording to these matching criteria, cases and controls had comparable
pre-exposure periods. Blood cultures were processed using the auto-
mated blood culture system BacT/Alert 3D (Biomérieux Inc., Marcy
l'Etoile, France). Conﬁrmation of Candida spp. identiﬁcation was per-
formed by use of Vitek-2 system (Biomérieux Inc.). Immunosuppressive
therapy was deﬁned as use of steroids (prednisolone N0.5 mg/kg/d or
equivalent for N1 month), chemotherapy or anti-tumor necrosis factor
therapy within the past 3 months. Previous antibiotic therapy was de-
ﬁned as exposure to antibiotics for at least 48 h in the 30 days preceding
candidemia, while concomitant antibiotic therapywas deﬁned as use of
antibiotic at the time of candidemia onset. Recent CDI was deﬁned as
CDI occurring in the 30 days before candidemia. Severe sepsis or septic
shock occurring during the days of candidemia were deﬁned according
to the Surviving Sepsis Campaign criteria [16]. Data about in-hospital
survival were also collected.
2.3. Study endpoint and statistical analysis
The goal of our studywas to identify risk factors independently asso-
ciated with the development of nosocomial candidemia in non-neutro-
penic patients hospitalized in IMWs. Moreover, we aimed to develop a
clinical score to identify patients with high risk of nosocomial
candidemia in IMWs.
Continuous variables were compared by Student's t-test if normally
distributed and the Mann–Whitney U test if non-normally distributed.
Categorical variables were evaluated using χ [2] or the two-tailed
Fisher's exact test. Values for continuous and categorical variables are
expressed as the mean ± standard deviation (SD) or median (inter-
quartile ranges) (IQR) and percentage of the group from which they
are derived, respectively. Multivariate analysis to identify independent
risk factors for development of candidemia was performed using a con-
ditional logistic regression model, to take into account matching. All
variables were considered for the multivariate analysis. At multivariate
analysis the predictors were selected via a stepwise selection procedure
optimizing the Akaike Information Criterion. It shall be noted that if the
initial pool of variables available for model selection at multivariate
analysis was restricted only to variables signiﬁcant at univariate analy-
sis, the same ﬁnal multivariate model was obtained. Odds ratio (OR)
and 95% conﬁdence intervals (CIs) were calculated to evaluate the
strength of any association.
A new score predicting the risk of nosocomial candidemia was de-
veloped. The score values were derived by rounding the beta coefﬁ-
cients (logarithm of the odds-ratios). We evaluated discrimination
using average receiver operating characteristic curves (AROC). AROC is
used to take into account the fact that data are matched. First, covari-
ate-speciﬁc ROC curves are estimated by means of a non-parametric
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3estimation procedure [17], then these are averaged [18].We proposed a
threshold based on maximization of Youden index. We calculated the
area under the curve (AUC) and the sensitivity and speciﬁcity for the
cut-off point of the score. Given that we are working with case-control
data, positive predictive value (PPV) and negative predictive value
(NPV) cannot be evaluated. However, based on the adaptation for inci-
dence of candidemia in our previous case series we provided the posi-
tive predictive value (PPV) and the negative predictive value (NPV) of
this score. To validate the model, we applied the derived risk score to
patients in the validation cohort. Statistical signiﬁcance was established
at ≤0.05. All reported p values are 2-tailed. The results obtained were
analyzed using commercially available statistical software packages
(SPSS, version 20.0; SPSS, Inc., Chicago, IL and R, version 3.0.2; R devel-
opment core team, Vienna, Austria).
3. Results
A total of 951 patients (317 cases of candidemia and 634 controls)
were included in the study. Among the 317 candidemic episodes, 165
(52%) were observed in Policlinico Umberto I, 113 (35.6%) in Azienda
Ospedaliera Universitaria Pisana and 39 (12.3%) in San Giovanni-
Addolorata Hospital. C. albicans was the most commonly documented
species (51.4%), followed by C. parapsilosis-group (17.7%), C. tropicalis
(9.8%), C. glabrata (7.6%), C. krusei (2.5%), others (11%); ﬁve patients
(1.6%) had mixed Candida infection. Themedian time at risk in patients
with candidemia was 6 (IQR 2–15) days. In-hospital mortality among
patients with candidemia was 40.4%.
Table 1 describes the demographic and clinical features of patients
with and without candidemia. The median age was 76 (IQR 68.5–84)
years in patients with candidemia and 75 (IQR 69–84) years in controls.
Patients with candidemia hadmore frequently a CVC or PICC inserted, a
higher rate of diabetes mellitus, COPD, IBD, acute pancreatitis, history of
recent CDI and previous antibiotic therapy, and were more likely to re-
ceive concomitant antibiotics, chemotherapy and immunosuppressive
therapy.
Table 2 describes univariate andmultivariate analyses of risk factors
for candidemia in our population. The multivariate analysis identiﬁed
severe sepsis or septic shock (OR 12.544, 95% CI 5.426–29.00,
p b 0.001), recent CDI (OR 9.287, 95% CI 3.166–27.241, p b 0.001), diabe-
tes mellitus (OR 7.306, 95% CI 3.905–13.666, p b 0.001), TPN (OR 6.266,
95% CI 3.240–12.119, p b 0.001), COPD (OR 6.029, 95% CI 2.982–12.188,
p b 0.001), concomitant intravenous glycopeptide therapy (OR 5.863,
95% CI 2.138–16.078, p b 0.001), PICC inserted (OR 5.125, 95% CI
2.595–10.118, p b 0.001), previous antibiotic therapy (OR 3.315, 95%
CI 1.975–5.565, p b 0.001) and immunosuppressive therapy (OR 2.131,
95% CI 1.316–3.451 p = 0.002) as factors independently associated
with the risk of nosocomial candidemia.
Table 3 summarizes the Candida score and the points assigned to
each variable. The score ranges from 0 to 14. The threshold to deﬁne
low risk for nosocomial candidemia was 3. When the score was ≤3 the
percentage of candidemia was 6.5%, while this prevalence increased to
66.4% with a score N3. The threshold 3 lead to a sensitivity of 87% and
a speciﬁcity of 83%. The PPV and the NPV adapted for prevalence of
candidemia is 0.095% and 0.997 respectively.
Table 4 shows the number of patients with candidemia, the sensitiv-
ity and the speciﬁcity of the proposed tool for each score. When the
score is N5 the speciﬁcity is N95%.
Fig. 1 (panel A) shows the AROC curve of this score system in the
derivation cohort. The AUC of our model was high (0.973 95% CI
0.809–0.997, p b 0.001).
The performance of the scorewas evaluated in the validation cohort.
This cohort of patients consisted of 270 patients (90 patients with
candidemia and 180 controls). Demographics and clinical characteris-
tics of the validation cohort are listed in Table S1 while comparison of
demographics and underlying disease between the derivation and the
validation cohort is reported in Table S2 (see Supplementary material).
As shown in Fig. 1 (panel B) AUC of AROC curve in the validation cohort
was 0.867 (95% CI 0.710–0.931, p b 0.001).
4. Discussion
To our knowledge, this is the ﬁrst study that systematically assessed
the risk factors for candidemia in non-neutropenic, non-ICU patients re-
siding in IMWs. Our study reveals that IMW patients have some
inedited risk factors for candidemia, which seem to be peculiar for this
setting of patients.
Candidemia in non-neutropenic patients has been long considered
as a clinical syndrome occurring in ICU or in patients undergoing ab-
dominal surgerywith anastomotic leakage [19]. However, an increasing
number of episodes of candidemia are nowadays diagnosed in medical
wards. A study by Bassetti et al. conducted in ﬁve sites in Italy and
Spain between 2008 and 2010 showed that 49.7% of a total of 995
candidemia episodes occurred in IMWs [9]. On the same hand, Luzzati
et al. showed that 68% of all episodes of nosocomial candidemia in elder-
ly patients were diagnosed in IMWs [20], and two additional studies
conducted in other countries between 2006 and 2012 reported similar
Table 1
Comparison of patients with candidemia and patients without candidemia admitted in In-
ternal Medicine wards (derivation cohort).
Patients with
candidemia
Patients without
candidemia
p-ValueN = 317 (%) N = 634 (%)
Male 148 (46.7%) 358 (56.5%) 0.004
Age, median (IQR) 76 (68.5–84) 75 (69–84) 0.982
Diabetes mellitus 175 (55.2%) 195 (30.8%) b0.001
IBD 15 (4.7%) 5 (0.8%) b0.001
Chronic renal failure 94 (29.7%) 140 (22.1%) 0.011
COPD 83 (26.2%) 61 (9.6%) b0.001
Solid cancer 55 (17.4%) 128 (20.2%) 0.295
Organ transplantation 1 (0.3%) 1 (0.2%) 0.617
Recent Clostridium difﬁcile
infection
57 (18%) 17 (2.7%) b0.001
Previous surgery 35 (11%) 68 (10.7%) 0.883
Acute pancreatitis 3 (0.9%) 2 (0.3%) 0.205
Previous hospitalization 86 (27.1%) 146 (23%) 0.165
Previous antibiotic therapy 15 (55.2%) 143 (22.6%) b0.001
Concomitant antibiotic
therapy
235 (74.1%) 399 (62.9%) b0.001
Multiple concomitant
antibiotics
52 (16.4%) 70 (11%) 0.020
Type of concomitant
antibiotic
Penicillin 1 (0.3%) 10 (1.6%) 0.086
β lactam/β lactamase
inhibitors
106 (33.4%) 136 (21.5%) b0.001
Cephalosporin 19 (6%) 77 (12.1%) 0.003
Carbapenem 43 (13.6%) 51 (8%) 0.007
Glycopeptide 43 (13.6%) 14 (2.2%) b0.001
Fluoroquinolone 36 (11.4%) 90 (14.%) 0.223
Aminoglycoside 11 (3.5%) 15 (2.4%) 0.325
Other 23 (7.3%) 30 (4.7%) 0.110
Immunosuppressive therapy 179 (56.5%) 189 (29.8%) b0.001
Non steroidal
immunosuppressive
therapy
50 (15.8%) 43 (6.8%) b0.001
Steroids 129 (40.7%) 146 (23%) b0.001
Chemotherapy 48 (15.1%) 58 (9.1%) 0.006
CVC 73 (23%) 60 (9.5%) b0.001
PICC 112 (35.3%) 40 (6.3%) b0.001
TPN 143 (45.1%) 58 (9.1%) b0.001
Charlson comorbidity index,
median (IQR)
7 (6–9) 5 (4–6) b0.001
Severe sepsis or septic shock 111 (35%) 20 (3.2%) b0.001
In-hospital mortality 128 (40.4%) 76 (12%) b0.001
COPD = chronic obstructive pulmonary disease; IBD = inﬂammatory bowel disease;
CVC = central venous catheter; PICC = peripherally inserted central catheter; TPN =
total parenteral nutrition, IQR = interquartile ranges.
Bold type indicates statistically signiﬁcant p-values.
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4results (prevalence of candidemia in IMWs ranging from 47.8% to 52%)
[11,12].
Patients hospitalized in IMWs have some “traditional” risk factors
for candidemia, including immunosuppressive therapy, previous antibi-
otic therapy, diabetes mellitus and severe sepsis or septic shock at pre-
sentation [21]. Among inedited risk factors, it is noteworthy that CDI,
diagnosed in the previous 30 days, is a strong factor associatedwith nos-
ocomial candidemia in IMWs patients.
Patients with recent CDI could be at high risk to develop candidemia
for several reasons. First, the presence of recent CDI could be interpreted
as a surrogate marker of clinical frailty and previous healthcare expo-
sures. Furthermore, patientswith CDI aremore likely to receivemultiple
antibiotic therapies. Taken together, all these factors could contribute to
the development of candidemia. However, CDI could also represent a
factor increasing the risk of candidemia by other independent mecha-
nisms. It has been demonstrated that CDI may be involved in Candida
translocation causing severe mucosal injury and disruption of the intes-
tinal epithelial barrier [22–24], andwe previously found that severe CDI
is associated with the risk of subsequent candidemia [13,25–26]. Then,
we may assume that the impairment of gastrointestinal mucosa due
to CDI play a pivotal role as predisposing factors for candidemia in pa-
tients residing in IMWs.
Of interest, we also found a signiﬁcant relationship between
candidemia and concomitant intravenous glycopeptide therapy. Two
studies analyzing pediatric patients cared for in ICUs identiﬁed the use
of a glycopeptide as a risk factor for candidemia [27–28], and a similar
result was obtained in a matched case-control study on elderly patients
with nosocomial candidemia [13]. This phenomenon may be explained
by the fact that vancomycin decreases the total anaerobic gut bacterial
populations, increasing the enteric bacilli population levels and
allowing Candida albicans to proliferate in the gut [29].
Intravascular devices are established risk factors for candidemia. The
PICC (but not the CVC) resulted at the multivariate analysis a factor in-
dependently associatedwith candidemia in our cohort. PICC use has be-
come a common practice in non-ICU settings for administration of
antibiotics, chemotherapy and parenteral nutrition, but if PICC is associ-
ated with a lower risk of BSI than other devices is still debated [30]. In
children, PICC for ≥21 days and TPN were factors independently associ-
ated with central line–associated BSI and the most common pathogens
were coagulase-negative staphylococci followed by Candida parapsilosis
[31]. Tascini et al. recently conﬁrmed the presence of PICC was common
in patients with very early-onset candidemia in IMWs [32].
Finally, the association between COPD and candidemia could be par-
tially explained by the large use of antibiotic and steroidal immunosup-
pressive therapy in these patients.
Diagnosis of candidemia in patients residing in IMWs may be chal-
lenging for physicians, because the heterogeneity of patients population
Table 2
Univariate and multivariate analysis of risk factors for candidemia in Internal Medicine wards (derivation cohort).
Univariate analysis Multivariate analysis
OR
95.0% CI
p-Value OR
95.0% CI
p-ValueLower Upper Lower Upper
Male sex 0.675 0.515 0.885 0.004
Diabetes mellitus 2.774 2.100 3.665 b0.001 7.306 3.905 13.666 b0.001
IBD 6.248 2.250 17.352 b0.001
Chronic renal failure 1.487 1.096 2.019 0.011
COPD 3.332 2.316 4.794 b0.001 6.029 2.982 12.188 b0.001
Recent CDI 7.957 4.542 13.939 b0.001 9.287 3.166 27.241 b0.001
Previous antibiotic therapy 4.232 3.169 5.651 b0.001 3.315 1.975 5.565 b0.001
Ongoing antibiotic therapy 1.688 1.252 2.275 0.001
Multiple concomitant antibiotics 1.581 1.073 2.329 0.020
Concomitant β lactam/β LI 1.840 1.362 2.485 b0.001
Concomitant cephalosporin 0.461 0.274 0.777 0.003
Concomitant carbapenem 1.794 1.166 2.759 0.007
Concomitant IV glycopeptide therapy 6.950 3.740 12.915 b0.001 5.863 2.138 16.078 b0.001
Immunosuppressive therapy 3.054 2.309 4.040 b0.001 2.131 1.316 3.451 0.002
Steroids 2.294 1.715 3.067 b0.001
Non-steroidal immunosuppressive th. 2.574 1.670 3.967 b0.001
Chemotherapy 1.772 1.177 2.667 0.006
CVC 2.862 1.971 4.156 b0.001
TPN 8.162 5.757 11.571 b0.001 6.266 3.240 12.119 b0.001
PICC 8.113 5.469 12.036 b0.001 5.125 2.595 10.118 b0.001
Severe sepsis/septic shock 16.542 10.018 27.317 b0.001 12.544 5.426 29.001 b0.001
IBD= inﬂammatory bowel disease; COPD= chronic obstructive pulmonary disease; CDI = Clostridium difﬁcile infection; β LI= β lactamase inhibitors; IV= intravenous; CVC= central
venous catheter; TPN = total parenteral nutrition; PICC = peripherally inserted central catheter.
Table 3
Risk score for candidemia in patients hospitalized in IMWs.
Risk factor Points
Severe sepsis/septic shock +2.5
Recent Clostridium difﬁcile infection +2
Diabetes mellitus +2
TPN +1.5
COPD +1.5
Concomitant glycopeptide therapy +1.5
PICC +1.5
Previous antibiotic therapy +1
Immunosuppressive therapy +0.5
IMWs = Internal Medicine wards; TPN = total parenteral nutrition; PICC =
peripherally inserted central catheter.
Table 4
Distribution of single risk-predictive score and corresponding number of patients with
candidemia, sensitivity and speciﬁcity in the derivation cohort.
Predictive
score
value
No. of patients
with candidemia
No. of
patients
without
candidemia
Total no.
of patients Sensitivity Speciﬁcity
1 2 (6.1%) 31 (93.9%) 33 99% 41%
2 13 (9.8%) 120 (90.2%) 133 96% 57%
3 28 (51.9%) 26 (48.1%) 54 87% 83%
4 25 (64.1%) 14 (35.9%) 39 69% 91%
5 30 (66.7%) 15 (33.3%) 45 52% 95%
6 30 (90.9%) 3 (9.1%) 33 33% 98%
7 13 (76.5%) 4 (23.5%) 17 20% 99%
8 8 (88.9%) 1 (11.1%) 9 11% 99%
9 9 (100%) – 9 4% 100%
≥10 5 (100%) – 5 2% 100%
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5and the lack of speciﬁc symptoms. Furthermore, about 50% of episodes
of candidemia in this setting are not associated with fever [33], and
the diagnosis may be delayed. Since the mortality for candidemia dou-
bles if antifungal therapy is not delivered within the ﬁrst 24 h [34–35],
the knowledge of speciﬁc risk factors, along with the use of diagnostic
techniques such as serum beta-D glucan, could be useful for physicians
to exclude the presence of candidemia or, conversely, to early recognize
patients with suspected candidemia. The proposed risk score has a dual
clinical signiﬁcance. Patients with a negative risk score (≤3) have a low
probability of candidemia, and because the high NPV this tool could be
used by clinicians to avoid unnecessary empirical antifungal therapy.
Conversely, since the speciﬁcity of the score increases if the total score
is high (N5), it can be used to support the decision to start empirical/
pre-emptive antifungal therapy in IMWs patients presenting with sys-
temic inﬂammatory response syndrome.
Our study have some strengths, but also some limitations. Themajor
strengths of our study are that it considered the speciﬁc risk factors for
candidemia in a large population of patients hospitalized in IMWs, and
the data source were from a multicenter cooperation. Moreover, we
proposed a new risk score showing a good performance. The score
was also validated in an external population of patients hospitalized in
a tertiary-care hospital located in a different geographic area and its
good reliability was conﬁrmed. As shown in Supplementary material,
the external validation cohort represent a different but plausibly related
population. This could be interpreted as a strength of our study because
conﬁrms the good generalizability of our risk model.
However, some limitations should be acknowledged: because the
retrospective design of the study some information may be missed, in-
cluding demographic informations, previous diagnostic tests, and data
regarding Candida multi-site colonization. Moreover, although a stan-
dard formwas used, data were extracted by four different investigators
at each study center, and this may introduce a bias in the collection of
data. However, wewere able to study a large number of candidemic pa-
tients in four tertiary-care centers fromdifferent regions and to date this
is the largest study performed in the setting of IMWs.
Another study limitation is that both Candida albicans and non-
albicans species were jointly analyzed, although speciﬁc risk factors as-
sociated with candidemia due to different Candida species have been
previously reported [4]. However, the aim of our study was to provide
a clinical tool easy to apply at bedside in patients with signs and symp-
toms of BSI prior to the blood cultures results rather than to analyze risk
factors for different Candida species. Future studies, speciﬁcally
designed, will differentiate between risk factors for albicans vs non-
albicans Candida spp. among IMWs patients.
In conclusion, we have reported that in patients admitted to IMWs
risk factors for candidemia are partially different from those already
established in patients cared for in ICUs or in surgical wards. Severe sep-
sis or septic shock, recent CDI, diabetes mellitus, TPN, COPD, concomi-
tant intravenous glycopeptide therapy, presence of PICC, previous
antibiotic therapy and immunosuppressive therapy are factors directly
associated with candidemia in non-neutropenic patients admitted to
IMWs. The recognition of these risk factors is necessary to identify pa-
tients requiring early antifungal therapy. To facilitate this identiﬁcation,
a “nine items” risk score for candidemia in IMWs can be easily used in
the clinical practice.
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